Trial Profile
A US-based study to evaluate the risk of myelodysplastic syndrome (MDS) in patients treated with bendamustine for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Flatiron Health database
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2017
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 27 Jun 2017 New trial record
- 06 Jun 2017 Results characterizing CLL patients receiving first-line bendamustine plus rituximab therapy (n=738), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology